Lenvatinib Delays Thyroid Cancer Progression

July 4, 2014
Josh Kremer, MD
Josh Kremer, MD

Josh Kremer, MD, vice president of clinical development at Eisai, Inc, discusses results of the phase III SELECT trial, which studied lenvatinib in radioiodine-refractory differentiated thyroid cancer.

In this video, Josh Kremer, MD, vice president of clinical development at Eisai, Inc, discusses results of the phase III SELECT trial, which found that lenvatinib extends progression-free survival in patients with radioiodine-refractory differentiated thyroid cancer from 3.6 months to 18.3 months. Dr. Kremer discusses where the drug falls in the current armamentarium for thyroid cancer treatment, and what other trial programs are currently underway for lenvatinib.